Resilience Capabilities Update May 2026: Large Molecule

Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably.

For sponsors seeking speed, reliability, and partnership-driven execution, this overview highlights how modern CDMO infrastructure is evolving to meet growing pipeline demands. Explore the full session to see how these capabilities translate into measurable program outcomes.